Skip to main content
SpringerLink
Log in

The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin

  • Rapid Communication
  • Biological Psychiatry
  • Published:
Journal of Neural Transmission Aims and scope Submit manuscript

Summary

The apparent antipsychotic action of the selective 5-HT2a receptor antagonist M100907 in MK-801-treated NMRI mice was shown to be markedly counteracted by the 5-HT2a/2c receptor antagonist ritanserin. The mechanism of action and potential implications are discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Baxter G, Kennett G, Blaney F, Blackburn T (1995) 5-HT2 receptor subtypes: a family reunited? Trends Pharmacol Sci 16: 105–10

    PubMed  Google Scholar 

  • Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N (1990) 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol 13: 500–6

    PubMed  Google Scholar 

  • Bunney BG, Bunney WE, Carlsson A (1995) Schizophrenia and glutamate. In: Bloom FE, Kupfer DJ (eds) Psychopharmacology: the fourth generation of progress. Raven Press, New York, pp 1205–1215

    Google Scholar 

  • Carlsson ML (1995) The selective 5-HT2a-receptor antagonist MDL100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse implications for psychosis. J Neural Transm [Gen Sect] 100: 225–237

    Google Scholar 

  • Devaud LL, Hollingsworth EB, Cooper BR (1992) Alterations in extracellular and tissue levels of biogenic amines in rat brain induced by the serotonin2 receptor antagonist, ritanserin. J Neurochem 59: 1459–1466

    PubMed  Google Scholar 

  • Duinkerke SJ, Botter PA, Jansen AA, van Dongen PA, van Haaften AJ, Boom AJ, van Laarhoven JH, Busard HL (1993) Ritanserin, a selective 5-HT2/1C antagonist, and negative symptoms in schizophrenia. A placebo-controlled double-blind trial [see comments]. Br J Psychiatry 163: 451–5

    PubMed  Google Scholar 

  • Hansson LO, Waters N, Winblad B, Gottfries CG, Carlsson A (1994) Evidence for biochemical heterogeneity in schizophrenia: a multivariate study of monoaminergic indices in human post-mortal brain tissue. J Neural Transm [Gen Sect] 98: 217–35

    Google Scholar 

  • Kehne JH, Baron BM, Carr AA, Chaney SF, Elands J, Feldman DJ, Frank RA, van Giersbergen PL, McCloskey TC, Johnson MP, McCarty DR, Poirot M, Senyah Y, Siegel BW, Widmaier C (1996) Preclinical characterization of the potential of the putative atypical antipsychotic MDL 100,907 as a potent 5-HT2A antagonist with a favorable CNS safety profile. J Pharmacol Exp Ther 277: 968–81

    PubMed  Google Scholar 

  • Leysen JE (1990) Gaps and peculiarities in 5-HT2 receptor studies. Neuropsychopharmacol 3: 361–69

    Google Scholar 

  • Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PF, Laduron PM (1985) Receptor-binding properties in vitro and in vivo of ritanserin: a very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 27: 600–11

    PubMed  Google Scholar 

  • Martin P, Waters N, Holm S, Carlsson A, Carlsson ML (1995) The stimulation of forward locomotion by MK-801 is abolished by low doses of the 5-HT2a antagonist MDL 100,907. 25th Annual Meeting, Society for Neuroscience, 21, part 3, p 2057

    Google Scholar 

  • Middlemiss DN, Tricklebank MD (1992) Centrally active 5-HT receptor agonists and antagonists. Neurosci Biobehav Rev 16: 75–82

    PubMed  Google Scholar 

  • Shi WX, Nathaniel P, Bunney BS (1995) Ritanserin, a 5-HT2A/2C antagonist, reverses direct dopamine agonist-induced inhibition of midbrain dopamine neurons. J Pharmacol Exp Ther 274: 735–40

    PubMed  Google Scholar 

  • Van Wijngaarden I, Tulp MT, Soudijn W (1990) The concept of selectivity in 5-HT receptor research. Eur J Pharmacol 188: 301–12

    PubMed  Google Scholar 

  • Waters N, Carlsson A, Hansson L (1994) An animal model of schizophrenia based on multivariate analysis monoaminergic biochemistry and behaviour 24th Annual Meeting, Society for Neuroscience, 20, part 1, p 825

    Google Scholar 

  • Wong EH, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL (1986) The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA 83: 7104–8

    PubMed  Google Scholar 

Download references

Author information

Author notes

  1. P. Martin

    Present address: Department of Pharmacology, Göteborg University, Sweden

Authors and Affiliations

  1. Department of Pharmacology, Göteborg University, Sweden

    N. Waters, A. Carlsson & M. L. Carlsson

Authors
  1. P. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Waters
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Carlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. L. Carlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Martin, P., Waters, N., Carlsson, A. et al. The apparent antipsychotic action of the 5-HT2a receptor antagonist M100907 in a mouse model of schizophrenia is counteracted by ritanserin. J. Neural Transmission 104, 561–564 (1997). https://doi.org/10.1007/BF01277672

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01277672

Keywords

Search

Navigation